JP2021504349A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021504349A5 JP2021504349A5 JP2020528252A JP2020528252A JP2021504349A5 JP 2021504349 A5 JP2021504349 A5 JP 2021504349A5 JP 2020528252 A JP2020528252 A JP 2020528252A JP 2020528252 A JP2020528252 A JP 2020528252A JP 2021504349 A5 JP2021504349 A5 JP 2021504349A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- thymosin
- item
- derivative
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762590444P | 2017-11-24 | 2017-11-24 | |
| US62/590,444 | 2017-11-24 | ||
| PCT/KR2018/014522 WO2019103523A2 (ko) | 2017-11-24 | 2018-11-23 | 티모신 베타 4 또는 이의 유도체를 유효성분으로 포함하는 술잔세포 증식 또는 뮤신 분비 촉진용 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021504349A JP2021504349A (ja) | 2021-02-15 |
| JP2021504349A5 true JP2021504349A5 (https=) | 2021-12-23 |
Family
ID=66630753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020528252A Pending JP2021504349A (ja) | 2017-11-24 | 2018-11-23 | チモシンβ４またはその誘導体を有効成分として含む杯細胞増殖またはムチン分泌を促進するための組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200353052A1 (https=) |
| EP (1) | EP3715451A4 (https=) |
| JP (1) | JP2021504349A (https=) |
| KR (1) | KR20200081402A (https=) |
| CN (1) | CN111386337A (https=) |
| AU (1) | AU2018372396A1 (https=) |
| CA (1) | CA3083101A1 (https=) |
| WO (1) | WO2019103523A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112023027B (zh) * | 2020-07-21 | 2023-03-14 | 广东海洋大学 | 胸腺素或其衍生物的应用和治疗快感缺乏型抑郁症的药物 |
| CN111888463B (zh) * | 2020-08-18 | 2021-09-21 | 华中农业大学 | 用于治疗抑郁症的胸腺素β4药物制剂与制备方法及其应用 |
| WO2024233903A1 (en) * | 2023-05-11 | 2024-11-14 | Wayne State University | Combination treatments to promote epithelial integrity and treat ocular disorders |
| KR20250098014A (ko) * | 2023-12-21 | 2025-07-01 | 주식회사 비제이와이 | 탈모 예방 또는 발모 촉진용 흉선 유래 펩타이드 유도체 및 이의 이용 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5032392A (en) * | 1986-09-04 | 1991-07-16 | Vision Pharmaceuticals | Aqueous ophthalmic solutions for the treatment of dryness and/or irritation of human or animal eyes |
| US20110020449A1 (en) * | 1998-07-30 | 2011-01-27 | Regenerx Biopharmaceuticals, Inc. | Methods of treating disorders of the eye and surrounding tissue with thymosin beta 4 (tb4), analogues, isoforms and other derivatives |
| AU2002255736B2 (en) * | 2001-03-15 | 2006-08-31 | Regenerx, Biopharmaceuticals, Inc. | Methods of treating disorders of the eye and surrounding tissue with thymosin beta4 (Tbeta4), analogues, isoforms and other derivatives |
| AU2003223601A1 (en) * | 2002-04-12 | 2003-10-27 | King's College London | ANTI-INFLAMMATORY AND WOUND HEALING EFFECTS OF LYMPHOID THYMOSIN Beta 4 |
| JP2008543877A (ja) * | 2005-06-17 | 2008-12-04 | リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド | Ｌｋｋｔｅｔおよび／またはｌｋｋｔｎｔ組成物および組織の悪化、傷害または損傷を処置または予防するための方法 |
| CN100484957C (zh) * | 2005-09-23 | 2009-05-06 | 北京诺思兰德生物技术股份有限公司 | 胸腺素β4衍生物及其应用 |
| CN1896096A (zh) * | 2005-07-15 | 2007-01-17 | 北京诺思兰德生物技术有限责任公司 | 基因工程方法生产的高活性胸腺素β4衍生物 |
| RU2010114005A (ru) * | 2007-09-11 | 2011-10-20 | Мондобайотек Лабораториз Аг (Li) | Применение сочетания пептидов тимозина бета4 и индуцирующего дельта-сон пептида в качестве терапевтического средства |
| US9504730B2 (en) * | 2010-09-30 | 2016-11-29 | Regenerx Biopharmaceuticals, Inc. | Method of achieving a thymosin beta 4 concentration in a human patient |
| KR20160047321A (ko) * | 2014-10-22 | 2016-05-02 | 주식회사 지트리파마슈티컬 | 티모신 베타 4 를 함유하는 조성물 |
| WO2016064078A1 (ko) * | 2014-10-22 | 2016-04-28 | 주식회사 지트리비앤티 | 티모신 베타 4를 함유하는 조성물 및 이를 포함하는 약학적 제형 |
| CN106692949B (zh) * | 2016-12-23 | 2022-03-15 | 北京诺思兰德生物技术股份有限公司 | 一种用于治疗眼部疾病的药物及其组合物 |
| KR102340750B1 (ko) * | 2017-03-03 | 2021-12-21 | 에이치엘비테라퓨틱스 주식회사 | 티모신 베타 4를 유효성분으로 포함하는 안정화된 외용 제제 |
-
2018
- 2018-11-23 JP JP2020528252A patent/JP2021504349A/ja active Pending
- 2018-11-23 AU AU2018372396A patent/AU2018372396A1/en not_active Abandoned
- 2018-11-23 WO PCT/KR2018/014522 patent/WO2019103523A2/ko not_active Ceased
- 2018-11-23 KR KR1020207013814A patent/KR20200081402A/ko not_active Withdrawn
- 2018-11-23 CN CN201880076169.1A patent/CN111386337A/zh active Pending
- 2018-11-23 CA CA3083101A patent/CA3083101A1/en active Pending
- 2018-11-23 US US16/765,929 patent/US20200353052A1/en not_active Abandoned
- 2018-11-23 EP EP18880309.2A patent/EP3715451A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021504349A5 (https=) | ||
| JP2019533722A5 (https=) | ||
| JP2020023567A5 (https=) | ||
| NZ602685A (en) | Concentrated protein formulations and uses thereof | |
| JP2005519914A5 (https=) | ||
| JP2017532343A5 (https=) | ||
| JP2014051497A5 (https=) | ||
| HRP20170445T1 (hr) | Poboljšani rekonstituirani pripravak surfaktanta koji sadrži analoge surfaktant-proteina b (sp-b) i surfaktant-proteina c (sp-c) | |
| PE20241305A1 (es) | Analogos de amilina | |
| RU2016150678A (ru) | ХЛОРИДНАЯ СОЛЬ ПЕПТИДА TAT-NR2B9с, КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
| JP2011105739A5 (https=) | ||
| JP2015057436A5 (https=) | ||
| JP2015527402A5 (https=) | ||
| JP2011032286A5 (https=) | ||
| NZ608502A (en) | Polypeptides that bind to human complement component c5 | |
| FI3294345T3 (fi) | Tpp1-formulaatioita ja menetelmiä cln2-taudin hoitamiseksi | |
| JPWO2019156137A5 (https=) | ||
| JP2015510393A5 (https=) | ||
| JP2010536714A5 (https=) | ||
| PE20141265A1 (es) | Formulaciones liofilizadas de fgf-18 | |
| JP2017002035A5 (https=) | ||
| JP2014515747A5 (https=) | ||
| JP2017527618A5 (https=) | ||
| IL308112A (en) | An active dominant YAP gene, which activates HIPPO, causes chromatin accessibility and cardiac muscle cell renewal | |
| HRP20201696T1 (hr) | Farmaceutska parenteralna formulacija koja sadrži kargluminsku kiselinu |